Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

26.10
+0.12000.46%
Post-market: 26.100.00000.00%19:30 EDT
Volume:1.18M
Turnover:31.06M
Market Cap:4.87B
PE:-7.79
High:26.87
Open:26.22
Low:26.02
Close:25.98
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:6.94
PE(LYR):-7.51

Loading ...

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jul 22

Should FDA Priority Review of Dyne’s DMD Drug Candidate Reshape Risk Expectations for Dyne Therapeutics (DYN) Investors?

Simply Wall St.
·
Jul 21

Dyne Therapeutics Advances DYNE-251 With FDA Priority Review

TIPRANKS
·
Jul 20

Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA

TIPRANKS
·
Jul 20

Dyne Says FDA Accepts Z-rostudirsen BLA for Exon 51 Duchenne Muscular Dystrophy Under Priority Review

Reuters
·
Jul 20

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (bla) for Z-rostudirsen in Exon 51 Duchenne Muscular Dystrophy (dmd)

THOMSON REUTERS
·
Jul 20

Dyne Therapeutics, Inc: Continues to Expect a Potential U.S. Launch of Z-rostudirsen in Q1 2027

THOMSON REUTERS
·
Jul 20

Dyne Therapeutics, - FDA Grants Priority Review with Pdufa Date January 21, 2027

THOMSON REUTERS
·
Jul 20

Insider Move at Dyne Therapeutics Sparks Fresh Investor Buzz

TIPRANKS
·
Jul 09

Dyne Therapeutics Director Jason P. Rhodes Reports Sale of 777,451 Shares Worth USD 17.83 Million

Reuters
·
Jul 09

Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 01

Dyne Therapeutics Director Jason P. Rhodes Disposes of Common Shares Worth $10.66 Million

Reuters
·
Jul 01

Top Executive’s Sudden Stock Move Sends a Fresh Signal to Dyne Investors

TIPRANKS
·
Jun 27

Dyne Therapeutics Director Jason P. Rhodes Reports $5.15 Million Common Share Disposal

Reuters
·
Jun 26

Dyne Therapeutics, Inc : TD Cowen Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Jun 26

TD Cowen Initiates Dyne Therapeutics at Buy

MT Newswires Live
·
Jun 26

Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential

TIPRANKS
·
Jun 26

U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex

Reuters
·
Jun 26

Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?

Simply Wall St.
·
Jun 25

Dyne Director Dirk Kersten Reports Disposal of Dyne Therapeutics Common Shares Worth $5.44 Million

Reuters
·
Jun 25